Literature DB >> 7435291

Effect of antifibrinolytic therapy on subarachnoid fibrosis in dogs after experimental subarachnoid haemorrhage.

M Ishii, S Suzuki, T Iwabuchi, J Julow.   

Abstract

The effect of antifibrinolytic therapy on posthaemorrhagic subarachnoid fibrosis was observed experimentally in dogs with the scanning electron microscope (SEM). The subchronic subjects, given intravenous injections of tranexamic acid (1 mg/day) for 12 days and sacrificed 3 weeks after cisternal blood injection, showed residual clot with thick fibrosis, especially around the haemorrhage. The chronic subjects, to which the same procedure was applied and which were sacrificed three months after cisternal blood injection, showed significant increases in the subarachnoid fibrosis, most remarkably in the parasagittal region. Tranexamic acid is widely used for preventing the recurrence of subarachnoid haemorrhage. However, it was revealed in this study that antifibrinolytic therapy might increase chronic posthaemorrhagic subarachnoid fibrosis, which is considered to be responsible for communicating hydrocephalus by disturbing epicortical CSF flow.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7435291     DOI: 10.1007/bf01401939

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  16 in total

1.  Post-haemorrhagic subarachnoid fibrosis in dogs. Scanning electron microscopic observation and dye perfusion study.

Authors:  S Suzuki; M Ishii; T Iwabuchi
Journal:  Acta Neurochir (Wien)       Date:  1979       Impact factor: 2.216

2.  Arteriopathic complications during treatment of subarachnoid hemorrhage with epsilon-aminocaproic acid.

Authors:  V K Sonntag; B M Stein
Journal:  J Neurosurg       Date:  1974-04       Impact factor: 5.115

3.  Glomerular capillary thrombosis and acute renal failure after epsilon-amino caproic acid therapy.

Authors:  C Charytan; D Purtilo
Journal:  N Engl J Med       Date:  1969-05-15       Impact factor: 91.245

4.  Subarachnoid haemorrhage and communicating hydrocephalus scanning electron microscopic observations.

Authors:  M Ishii; S Suzuki; J Julow
Journal:  Acta Neurochir (Wien)       Date:  1979       Impact factor: 2.216

5.  Changes in the subarachnoid space after experimental subarachnoid haemorrhage in the dog: scanning electron microscopic observation.

Authors:  S Suzuki; M Ishii; M Ottomo; T Iwabuchi
Journal:  Acta Neurochir (Wien)       Date:  1977       Impact factor: 2.216

6.  Ventricular dilatation and communicating hydrocephalus following spontaneous subarachnoid hemorrhage.

Authors:  J Vassilouthis; A E Richardson
Journal:  J Neurosurg       Date:  1979-09       Impact factor: 5.115

7.  Treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm with tranexamic acid: a double-blind clinical trial.

Authors:  B Chandra
Journal:  Ann Neurol       Date:  1978-06       Impact factor: 10.422

8.  Tranexamic acid in the preoperative management of ruptured intracranial aneurysms.

Authors:  H Fodstad; B Liliequist; M Schannong; C A Thulin
Journal:  Surg Neurol       Date:  1978-07

9.  Recurrent subarachnoid hemorrhage associated with aminocaproic acid therapy and acute renal artery thrombosis. Case report.

Authors:  R R Tubbs; S P Benjamin; D E Dohn
Journal:  J Neurosurg       Date:  1979-07       Impact factor: 5.115

10.  Prevention of subarachnoid fibrosis after subarachnoid haemorrhage with urokinase. Scanning electron microscopic study in the dog.

Authors:  J Julow
Journal:  Acta Neurochir (Wien)       Date:  1979       Impact factor: 2.216

View more
  3 in total

Review 1.  Antifibrinolytic agents in subarachnoid haemorrhage.

Authors:  K W Lindsay
Journal:  J Neurol       Date:  1987-01       Impact factor: 4.849

2.  Rebleeding, ischaemia and hydrocephalus following anti-fibrinolytic treatment for ruptured cerebral aneurysms: a retrospective clinical study.

Authors:  G Pinna; A Pasqualin; C Vivenza; R Da Pian
Journal:  Acta Neurochir (Wien)       Date:  1988       Impact factor: 2.216

3.  LSKL peptide alleviates subarachnoid fibrosis and hydrocephalus by inhibiting TSP1-mediated TGF-β1 signaling activity following subarachnoid hemorrhage in rats.

Authors:  Fan Liao; Gaofeng Li; Wen Yuan; Yujie Chen; Yuchun Zuo; Kauthar Rashid; John H Zhang; Hua Feng; Fei Liu
Journal:  Exp Ther Med       Date:  2016-08-31       Impact factor: 2.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.